Should 68Ga-PSMA PET/CT Replace CT and Bone Scan in Clinical Staging of High-risk Prostate Cancer?

Background/Aim: To evaluate the accuracy of 68Gallium prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) vs. CT combined with bone scan in the clinical staging of high-risk prostate cancer (PCa). Patients and Methods: From January 2020 to October 2021, 30 patients underwent clinical staging according to 68Ga-PSMA PET/TC, lung-abdominal CT and Technetium-99m bone scan. Results: 68Ga-PSMA PET/CT demonstrated a better accuracy in comparison with CT plus bone scan in the diagnosis of node metastases at definitive histology (76.9% vs. 46.1%; p=0.001). Conclusion: The 68Ga-PSMA PET/CT was more accurate than CT and bone scan in the staging of high-risk PCa, leading to a change in the therapeutic strategy in 10% of the cases.

Automated summary

This study evaluated the accuracy of 68Gallium prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) versus CT combined with bone scan in the clinical staging of high-risk prostate cancer (PCa). The results showed that 68Ga-PSMA PET/CT had better accuracy in diagnosing node metastases, leading to a change in therapeutic strategy in 10% of the cases.